Table 1 Demographic and clinical data
n (%) | |
|---|---|
No. of patients | 32 |
Age (years), median (range) | 67 (47-84) |
PFS (median, IQR) | 229 (130.5 – 480.5) |
OS (median, IQR) | 521 (161 – 708) |
Gender (male) | 25 (78.1%) |
Histological type | |
Epithelioid | 24 (75%) |
Sarcomatoid | 2 (6.2%) |
Biphasic | 6 (18.7%) |
Received line of chemotherapy during the study | |
None | 4 (12.5%) |
1 | 19 (59.3%) |
2 | 7 (21.8%) |
4 | 2 (6.2%) |
Treatment schemes | |
Gemcitabine + cisplatin | 14 |
Gemcitabine + cisplatin/carboplatin | 3 |
Pemetrexed + cisplatin | 7 |
Pemetrexed + cisplatin/carboplatin | 4 |
Stage | |
I | 4 (12.5%) |
II | 2 (6.2%) |
III | 14 (43.7%) |
IV | 12 (37.5%) |
Asbestos exposure | 24 (75%) |